Clinical trials: Skin Cancer Face
Acne Vulgaris
Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of Acne
This study was conducted to determine the effects and side effects of ProOxy facial spray in the treatment of acne.
- Trial name
- NCT01682200
- Testing
- ProOxy
- Where
- 2 sites in Philippines
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medivet Pty Ltd
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant…
- Trial name
- NCT02866695
- Testing
- ingenol mebutate gel 0.015%
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or…
- Trial name
- NCT01820260
- Testing
- Ingenol mebutate gel
- Where
- United States
- Volunteers
- 395 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
The purpose of this study is to prove the safety and efficacy of Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution 20% followed by 10 J/cm2 of blue light delivered at 10 mW/cm2 or 20 mW/cm2 in the treatment of…
- Trial name
- NCT03024060
- Testing
- ALA, Vehicle, IBL 20 mW
- Where
- 7 sites in United States
- Sponsor
- DUSA Pharmaceuticals, Inc.
Skin Basal Cell Carcinoma
Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery
This clinical trial studies the effectiveness of narrow margins in patients with low-risk basal cell carcinoma undergoing surgery to remove skin lesions on the face.
- Trial name
- NCT02579551
- Testing
- Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Actinic Keratoses
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis…
- Trial name
- NCT03575780
- Testing
- KX2-391 Ointment 1%
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Athenex, Inc.
Nevus, Seborrheic Keratosis (SK)
Optimizing the Timing for Facial Surgical Dressing Removal
What is this study about? You are being invited to participate in a clinical research study because you are scheduled to undergo a facial skin surgery for your health condition.
- Conditions
- Nevus, Seborrheic Keratosis (SK), Cyst, Lipoma
- Trial name
- NCT07441538
- Testing
- sterile gauze dressing
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Actinic Keratosis
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment
- Trial name
- NCT02549339
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 383 people
- Sponsor
- LEO Pharma
Head Neck Cancer, Mouth Cancer
CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)
head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects areas such as the mouth, throat, and voice box. Despite medical progress, little has changed in the care for patients with HPV-negative cancer.
- Conditions
- Head Neck Cancer, Mouth Cancer, Throat Cancer, Larynx Cancer
- Trial name
- CAPTURE (NCT07254962)
- Testing
- Capecitabine, Standard of Care (SOC)
- Volunteers
- 75 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Head and Neck Cancer, Lymphedema of Face
Two Different Physiotherapy Programs in Lymphedema Following Head and Neck Cancer Treatment
The aim of this study was to determine the effects of complex decongestive physiotherapy (CDP) and home programs on internal/external lymphedema, staging, fibrosis, and three-dimensional (3D) surface scanning and volume…
- Conditions
- Head and Neck Cancer, Lymphedema of Face, Fibrosis; Skin
- Trial name
- NCT04286698
- Testing
- Complex decongestive physiotherapy, Home program
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Izmir Bakircay University
Actinic Keratoses
Daylight Photodynamic Therapy for Actinic Keratosis
This is a randomized, single-blind controlled trial with parallel group design to determine whether daylight photodynamic therapy (PDT) affords a reduction in treatment symptoms of pain, burning, and pruritus as measured by 1)…
- Trial name
- NCT03322293
- Testing
- Aminolevulinic Acid Topical 20% Topical Solution, BLU-U blue light phototherapy illuminator
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Actinic Keratosis
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
- Trial name
- NCT02838628
- Testing
- 50 mg of KX2-391 Ointment 1%
- Where
- 16 sites in United States
- Volunteers
- 168 people
- Sponsor
- Almirall, S.A.
Actinic Keratoses
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and…
- Trial name
- NCT04085367
- Testing
- MAL 16.8% cream, MAL Vehicle Cream
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Galderma R&D
Lentigo Maligna Melanoma (Head or Neck)
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Lentigo malignant (LM) is an intraepidermal melanocytic proliferation occurring on photoexposed skin. In our project, this term applies both to Dubreuilh's melanosis and to Dubreuilh's intraepidermal melanoma.
- Trial name
- ImiReduc (NCT01720407)
- Testing
- Imiquimod cream + surgery
- Where
- 22 sites in France
- Volunteers
- 259 people
- Sponsor
- Nantes University Hospital
Actinic Keratosis
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
The purpose of this study is to explore the effect of treating actinic keratoses of the face with imiquimod 3.75% cream followed by photodynamic therapy in comparison to treatment with imiquimod alone
- Trial name
- NCT01203878
- Testing
- Photodynamic therapy, Imiquimod
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tennessee Clinical Research Center
Actinic Keratoses
Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention
Background Actinic keratoses (AKs) are often treated separately, lesion by lesion. However, in the past years, AKs have been described as a field disease and not limited to single clinically apparent lesions.
- Trial name
- NCT03642535
- Testing
- ALA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Dermatology Hospital
Actinic Keratosis
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands
- Trial name
- NCT06319794
- Testing
- Bimiralisib
- Where
- 2 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- TORQUR
Dermatologic Complications, Malignant Neoplasm
Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab
This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab.
- Conditions
- Dermatologic Complications, Malignant Neoplasm, Pain
- Trial name
- NCT01393821
- Testing
- menadione topical lotion, questionnaire administration, management of therapy complications
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Actinic Keratosis
Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face
Interventional, monocentric, national, single-arm, uncontrolled, open, prospective phase IV study. Since this study is not powered for confirmative testing, analysis is done by descriptive statistics Eligible AK patients receive…
- Trial name
- SunDamage (NCT05900258)
- Testing
- Tirbanibulin
- Where
- Austria
- Volunteers
- 22 people
- Sponsor
- Medical University of Graz
Actinic Keratosis
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
Actinic keratoses (AK) are common cutaneous lesions associate with chronic ultraviolet radiation exposure. While most authorities consider AK as a pre-malignant lesion, some consider it as an incipient squamous cell carcinoma…
- Trial name
- NCT01836367
- Testing
- Ingenol Mebutate 0.015%
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai